US4401820A
(en)
|
1981-01-23 |
1983-08-30 |
Tanabe Seiyaku Co., Ltd. |
Process for racemizing optically active α-amino acids or a salt thereof
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
EP0365685B1
(en)
|
1988-03-30 |
1995-01-18 |
Toray Industries, Inc. |
Freeze-dried composition comprising a horseradish peroxidase-labelled Fab' fragment of an anti-human interferon-beta monclonal antibody and trehalose; EIA kit containing the composition
|
WO1989011297A1
(en)
|
1988-05-27 |
1989-11-30 |
Centocor, Inc. |
Freeze-dried formulation for antibody products
|
AU686113B2
(en)
|
1992-09-16 |
1998-02-05 |
Scripps Research Institute, The |
Human neutralizing monoclonal antibodies to respiratory syncytial virus
|
PT2275119E
(pt)
|
1995-07-27 |
2013-11-21 |
Genentech Inc |
Formulação de proteína liofilizada isotónica estável
|
ZA966075B
(en)
|
1995-07-27 |
1998-01-19 |
Genentech Inc |
Protein formulation.
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
CA2230116A1
(en)
|
1995-09-18 |
1997-03-27 |
Intracel Corporation |
Neutralizing monoclonal antibodies to respiratory syncytial virus
|
US7365166B2
(en)
|
1997-04-07 |
2008-04-29 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
EP1135415B1
(en)
|
1998-12-01 |
2010-08-11 |
Facet Biotech Corporation |
Humanized antibodies to gamma-interferon
|
US6586573B1
(en)
|
1999-02-22 |
2003-07-01 |
Baxter International Inc. |
Albumin-free Factor VIII formulations
|
CA2366706A1
(en)
|
1999-03-11 |
2000-09-14 |
Schering Corporation |
Mammalian cytokines; related reagents and methods
|
US7090847B1
(en)
|
1999-09-09 |
2006-08-15 |
Schering Corporation |
Mammalian cytokines; related reagents and methods
|
DE60038304T3
(de)
|
1999-09-09 |
2017-04-06 |
Merck Sharp & Dohme Corp. |
Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
|
EP1233790A2
(en)
|
1999-10-22 |
2002-08-28 |
Ludwig Institute For Cancer Research |
A33 antigen specific immunoglobulin products in cancer therapy
|
EP1324776B2
(en)
|
2000-10-12 |
2018-03-21 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
US6818216B2
(en)
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
EP1801123A3
(en)
|
2000-12-28 |
2007-11-21 |
Altus Pharmaceuticals Inc. |
Crystals of whole antibodies and fragments thereof and methods for making and using them
|
AU2002256971B2
(en)
|
2000-12-28 |
2008-04-03 |
Altus Pharmaceuticals Inc. |
Crystals of whole antibodies and fragments thereof and methods for making and using them
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
JP2005500304A
(ja)
|
2001-06-21 |
2005-01-06 |
アルタス バイオロジックス インコーポレイテッド |
球状タンパク質粒子およびそれらの作製方法および使用方法
|
ES2907826T3
(es)
|
2001-06-26 |
2022-04-26 |
Amgen Inc |
Anticuerpos para OPGL
|
WO2003009817A2
(en)
|
2001-07-25 |
2003-02-06 |
Protein Design Labs, Inc. |
Stable lyophilized pharmaceutical formulation of igg antibodies
|
ES2392073T3
(es)
|
2001-11-08 |
2012-12-04 |
Abbott Biotherapeutics Corp. |
Formulación farmacéutica líquida estable de anticuerpos IGG
|
DE10207178A1
(de)
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Komponenten für die Herstellung amphoterer Liposomen
|
US20030180287A1
(en)
*
|
2002-02-27 |
2003-09-25 |
Immunex Corporation |
Polypeptide formulation
|
CN1252130C
(zh)
|
2002-04-01 |
2006-04-19 |
北京键凯科技有限公司 |
亲水性聚合物与丹参酮类药物的结合物以及包含该结合物的药物组合物
|
AU2003226356A1
(en)
|
2002-04-12 |
2003-10-27 |
Ramot At Tel Aviv University Ltd. |
Prevention of brain inflammation as a result of induced autoimmune response
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
PT1537878E
(pt)
|
2002-07-03 |
2010-11-18 |
Ono Pharmaceutical Co |
Composições de imunopotenciação
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
WO2004019861A2
(en)
|
2002-08-28 |
2004-03-11 |
Pharmacia Corporation |
Stable ph optimized formulation of a modified antibody
|
WO2004055164A2
(en)
|
2002-12-13 |
2004-07-01 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
AU2003288675B2
(en)
|
2002-12-23 |
2010-07-22 |
Medimmune Limited |
Antibodies against PD-1 and uses therefor
|
EP2270051B1
(en)
|
2003-01-23 |
2019-05-15 |
Ono Pharmaceutical Co., Ltd. |
Antibody specific for human PD-1 and CD3
|
WO2004071517A2
(en)
|
2003-02-06 |
2004-08-26 |
Schering Corporation |
Uses of il-23 related reagents
|
KR20050110628A
(ko)
|
2003-02-10 |
2005-11-23 |
엘란 파마슈티칼스, 인크. |
면역글로불린 제제 및 이의 제조방법
|
TWI357336B
(en)
|
2003-03-10 |
2012-02-01 |
Schering Corp |
Uses of il-23 agonists and antagonists; related re
|
LT2335725T
(lt)
|
2003-04-04 |
2017-01-25 |
Genentech, Inc. |
Didelės koncentracijos antikūno ir baltymo kompozicijos
|
CN1816356A
(zh)
|
2003-05-14 |
2006-08-09 |
免疫原公司 |
药物缀合物组合物
|
EP1498123A1
(en)
|
2003-07-18 |
2005-01-19 |
Aventis Pharma S.A. |
Emulsifying systems containing azetidine derivatives
|
US20070212346A1
(en)
|
2003-10-09 |
2007-09-13 |
Tomoyuki Igawa |
Highly Concentrated Stabilized Igm Solution
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
WO2005047324A2
(en)
|
2003-11-10 |
2005-05-26 |
Schering Corp |
ANTI-INTERLEUKIN ANTIBODY-10
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
WO2005063291A1
(ja)
|
2003-12-25 |
2005-07-14 |
Kirin Beer Kabushiki Kaisha |
抗体を含有する安定な水性医薬製剤
|
EP1704166B1
(en)
|
2004-01-07 |
2015-04-29 |
Novartis Vaccines and Diagnostics, Inc. |
M-csf-specific monoclonal antibody and uses thereof
|
CA2555791A1
(en)
|
2004-02-12 |
2005-08-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Highly concentrated liquid formulations of anti-egfr antibodies
|
CA2556425A1
(en)
|
2004-02-17 |
2005-09-01 |
Schering Corporation |
Methods of modulating il-23 activity; related reagents
|
ES2376556T3
(es)
|
2004-03-24 |
2012-03-14 |
Abbott Biotherapeutics Corp. |
Utilización de la anticuerpos anti-alfa5beta1 para inhibir la proliferación de las células cancerosas.
|
AU2005249360B2
(en)
|
2004-04-12 |
2011-07-21 |
Medimmune, Llc |
Anti-IL-9 antibody formulations and uses thereof
|
EP1766396B1
(en)
|
2004-06-07 |
2010-08-11 |
Ramot at Tel-Aviv University Ltd. |
Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
GEP20115195B
(en)
|
2004-07-30 |
2011-04-11 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and use thereof
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US20080057070A1
(en)
|
2004-11-04 |
2008-03-06 |
Chiron Corporation |
Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
|
WO2006081587A2
(en)
|
2005-01-28 |
2006-08-03 |
Wyeth |
Stabilized liquid polypeptide formulations
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
DOP2006000029A
(es)
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
KR100996801B1
(ko)
|
2005-03-08 |
2010-11-25 |
파마시아 앤드 업존 캄파니 엘엘씨 |
항-MAdCAM 항체 조성물
|
CN101166763B
(zh)
|
2005-04-18 |
2012-09-19 |
伊达研究和发展有限公司 |
稳定的抗乙肝病毒(hbv)抗体配制剂
|
CN101163719A
(zh)
|
2005-04-22 |
2008-04-16 |
伊莱利利公司 |
TGFβ1特异性抗体
|
KR101498834B1
(ko)
|
2005-05-09 |
2015-03-05 |
오노 야꾸힝 고교 가부시키가이샤 |
예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
EP3260465A1
(en)
|
2005-06-07 |
2017-12-27 |
ESBATech, an Alcon Biomedical Research Unit LLC |
Stable and soluble antibodies inhibiting tnf-alpha
|
CN101287761A
(zh)
|
2005-06-15 |
2008-10-15 |
先灵公司 |
抗-igf1r抗体制剂
|
PT1896073E
(pt)
|
2005-06-30 |
2013-05-28 |
Janssen Biotech Inc |
Composições, métodos e aplicações de anticorpos anti-il-23
|
JP2009502972A
(ja)
|
2005-07-29 |
2009-01-29 |
アムジエン・インコーポレーテツド |
タンパク質凝集を抑制する製剤
|
KR101566393B1
(ko)
|
2005-08-03 |
2015-11-05 |
이뮤노젠 아이엔씨 |
면역접합체 제형
|
PT1937721E
(pt)
|
2005-08-25 |
2010-09-17 |
Lilly Co Eli |
Anticorpos anti-il-23
|
RS55788B1
(sr)
|
2005-08-31 |
2017-08-31 |
Merck Sharp & Dohme |
Inženjerisana anti-il-23 antitela
|
EA014025B1
(ru)
|
2005-09-12 |
2010-08-30 |
Новиммун С.А. |
Композиции антитела против cd3
|
EP1942939B2
(en)
|
2005-09-30 |
2021-07-07 |
Medimmune Limited |
Interleukin-13 antibody composition
|
EP1977763A4
(en)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
STABILIZER PREPARATION CONTAINING ANTIBODIES
|
MX2008008621A
(es)
|
2005-12-29 |
2008-11-27 |
Centocor Inc |
Anticuerpos anti-il-23 humanos, composiciones, metodos y usos.
|
JP2009525986A
(ja)
|
2006-02-03 |
2009-07-16 |
メディミューン,エルエルシー |
タンパク質製剤
|
CA2647111A1
(en)
|
2006-03-28 |
2007-10-04 |
F. Hoffmann-La Roche Ag |
Anti-igf-1r human monoclonal antibody formulation
|
WO2007124082A2
(en)
|
2006-04-21 |
2007-11-01 |
Amgen, Inc. |
Buffering agents for biopharmaceutical formulations
|
AR060487A1
(es)
|
2006-04-21 |
2008-06-18 |
Xoma Technology Ltd |
Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
|
AU2007260787A1
(en)
|
2006-06-13 |
2007-12-21 |
Zymogenetics, Inc |
IL-17 and IL-23 antagonists and methods of using the same
|
US20080112953A1
(en)
|
2006-10-06 |
2008-05-15 |
Amgen Inc. |
Stable formulations
|
ES2925992T3
(es)
|
2006-10-20 |
2022-10-20 |
Amgen Inc |
Formulaciones estables de polipéptidos
|
CA2667655A1
(en)
|
2006-10-27 |
2008-05-15 |
Abbott Biotechnology Ltd. |
Crystalline anti-htnfalpha antibodies
|
WO2008068246A1
(en)
|
2006-12-05 |
2008-06-12 |
Crucell Holland B.V. |
Liquid anti-rabies antibody formulations
|
KR20090088950A
(ko)
|
2006-12-14 |
2009-08-20 |
쉐링 코포레이션 |
가공된 항-tslp 항체
|
US20080213282A1
(en)
|
2006-12-21 |
2008-09-04 |
Jaby Jacob |
Formulations
|
MX2009007406A
(es)
|
2007-01-09 |
2010-01-25 |
Wyeth Corp |
Formulaciones de anticuerpo anti-il-13 y usos de las mismas.
|
TWI426918B
(zh)
|
2007-02-12 |
2014-02-21 |
Merck Sharp & Dohme |
Il-23拮抗劑於治療感染之用途
|
WO2008103473A1
(en)
|
2007-02-23 |
2008-08-28 |
Schering Corporation |
Engineered anti-il-23p19 antibodies
|
RS52345B
(en)
|
2007-02-23 |
2012-12-31 |
Schering Corporation |
ANTI-IL-23P19 ANTIBODY MANUFACTURED BY GENETIC ENGINEERING
|
RU2476442C2
(ru)
|
2007-03-29 |
2013-02-27 |
Эббот Лэборетриз |
Кристаллические антитела против il-12 человека
|
WO2008121615A2
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Inc. |
Antibody formulation
|
US20090208492A1
(en)
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
AR067011A1
(es)
|
2007-06-14 |
2009-09-30 |
Biogen Idec Inc |
Formulaciones de anticuerpos
|
DK2170959T3
(da)
*
|
2007-06-18 |
2014-01-13 |
Merck Sharp & Dohme |
Antistoffer mod human programmeret dødsreceptor pd-1
|
MX2009013886A
(es)
|
2007-06-25 |
2010-01-27 |
Amgen Inc |
Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos.
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
US20100286038A1
(en)
|
2007-09-21 |
2010-11-11 |
Valentyn Antochshuk |
Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
|
EP2205276A4
(en)
|
2007-09-28 |
2012-08-15 |
Janssen Biotech Inc |
ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
|
AR068723A1
(es)
|
2007-10-05 |
2009-12-02 |
Glaxo Group Ltd |
Proteina que se une a antigenos que se une a il-23 humana y sus usos
|
WO2009070642A1
(en)
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
ES2511844T3
(es)
|
2007-12-21 |
2014-10-23 |
F. Hoffmann-La Roche Ag |
Formulación de anticuerpo
|
PE20091174A1
(es)
*
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
JP2011507922A
(ja)
|
2007-12-28 |
2011-03-10 |
バイオインヴェント インターナショナル アーベー |
配合物
|
KR20100138908A
(ko)
|
2008-02-07 |
2010-12-31 |
암젠 인코퍼레이티드 |
안정화된 단백질 조성물
|
ES2639857T3
(es)
|
2008-02-11 |
2017-10-30 |
Cure Tech Ltd. |
Anticuerpos monoclonales para el tratamiento del tumor
|
WO2009120684A1
(en)
|
2008-03-25 |
2009-10-01 |
Medimmune, Llc |
Antibody formulation
|
CA3179151A1
(en)
|
2008-04-09 |
2009-10-15 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
EP3002299A1
(en)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
US8460886B2
(en)
|
2008-07-04 |
2013-06-11 |
Ono Pharmaceutical Co., Ltd. |
Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
|
MX2011002159A
(es)
|
2008-08-27 |
2011-03-29 |
Schering Corp |
Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria.
|
ES2658596T3
(es)
|
2008-09-19 |
2018-03-12 |
Pfizer Inc. |
Formulación líquida estable de anticuerpos
|
MX345226B
(es)
|
2008-10-29 |
2017-01-20 |
Ablynx Nv |
Formulaciones de moleculas de union a antigeno de dominio sencillo.
|
WO2010062372A2
(en)
|
2008-11-03 |
2010-06-03 |
President And Fellows Of Harvard College |
Methods for modulating nf-kb using gibberellins
|
CN102281902B
(zh)
|
2008-11-17 |
2013-11-13 |
弗·哈夫曼-拉罗切有限公司 |
用于减少大分子在生理条件下聚集的方法和制剂
|
WO2010069858A1
(en)
|
2008-12-19 |
2010-06-24 |
F. Hoffmann-La Roche Ag |
Pharmaceutical composition
|
AU2010221099A1
(en)
|
2009-03-06 |
2011-09-22 |
Medimmune, Llc |
Humanized anti-CD19 antibody formulations
|
CN102414221A
(zh)
|
2009-03-06 |
2012-04-11 |
健泰科生物技术公司 |
抗体配制剂
|
EP2230312A1
(en)
|
2009-03-19 |
2010-09-22 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Probe compound for detecting and isolating enzymes and means and methods using the same
|
CN104490767A
(zh)
|
2009-05-04 |
2015-04-08 |
艾伯维生物技术有限公司 |
人抗TNF-α抗体的稳定高蛋白质浓度制剂
|
US9155745B2
(en)
|
2009-06-16 |
2015-10-13 |
Universite De Geneve |
Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
|
WO2011008770A2
(en)
|
2009-07-14 |
2011-01-20 |
Biogen Idec Ma Inc. |
Methods for inhibiting yellow color and peroxide formation in a composition
|
EP2458990B1
(en)
|
2009-07-28 |
2016-03-30 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
WO2011024862A1
(ja)
|
2009-08-31 |
2011-03-03 |
三洋化成工業株式会社 |
タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及び液体洗剤組成物、並びに、この安定化剤を用いるタンパク質の安定化方法
|
AU2010289677B2
(en)
|
2009-09-03 |
2014-07-31 |
Merck Sharp & Dohme Llc |
Anti-GITR antibodies
|
US20110059079A1
(en)
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Antibody Coformulations
|
KR101530417B1
(ko)
|
2009-09-15 |
2015-06-19 |
알테아 테크놀로지스, 인코포레이티드 |
단백질 a 결정 및 가교 결합된 결정 및 이들의 사용 방법
|
PE20121646A1
(es)
|
2009-11-04 |
2012-12-02 |
Merck Sharp & Dohme |
Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica
|
US20110226650A1
(en)
|
2009-12-21 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
JP2013515754A
(ja)
|
2009-12-29 |
2013-05-09 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規な抗体製剤
|
TWI505838B
(zh)
|
2010-01-20 |
2015-11-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody solution containing
|
BR112012023895A2
(pt)
|
2010-03-17 |
2016-11-29 |
Abbott Res Bv |
composições de anti-fator de crescimento do nervo (ngf)
|
JP2013525484A
(ja)
|
2010-05-03 |
2013-06-20 |
ジェネンテック, インコーポレイテッド |
タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
|
CN103402516B
(zh)
|
2010-06-17 |
2018-01-30 |
富津世生物技术有限公司 |
用作抗病毒药物的化合物、组合物及使用方法
|
EP2399604A1
(en)
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Novel antibody formulation
|
WO2012018538A2
(en)
|
2010-07-26 |
2012-02-09 |
Schering Corporation |
Bioassays for determining pd-1 modulation
|
CA2813587C
(en)
|
2010-10-06 |
2019-01-15 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
|
EP2648750B1
(en)
|
2010-12-10 |
2017-01-25 |
Novartis AG |
Antibody formulation
|
CA2830538C
(en)
|
2011-03-25 |
2020-05-12 |
Amgen Inc. |
Anti - sclerostin antibody crystals and formulations thereof
|
LT2691112T
(lt)
*
|
2011-03-31 |
2018-07-25 |
Merck Sharp & Dohme Corp. |
Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
|
US20140044727A1
(en)
|
2011-04-07 |
2014-02-13 |
Glaxosmithkline Llc |
Formulations with reduced viscosity
|
UY34105A
(es)
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
US9574005B2
(en)
|
2011-07-19 |
2017-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stable Protein-containing preparation containing argininamide or analogous compound thereof
|
MX363734B
(es)
|
2011-10-27 |
2019-03-29 |
Massachusetts Inst Technology |
Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco.
|
NZ627859A
(en)
|
2012-01-23 |
2015-09-25 |
Regeneron Pharma |
Stabilized formulations containing anti-ang2 antibodies
|
CN104159614A
(zh)
|
2012-03-07 |
2014-11-19 |
卡迪拉保健有限公司 |
TNF-α抗体的药物制剂
|
IN2014DN09127A
(es)
*
|
2012-04-03 |
2015-05-22 |
Univ St Andrews |
|
WO2013165791A1
(en)
|
2012-05-03 |
2013-11-07 |
Boehringer Ingelheim International Gmbh |
Anti-il-23p19 antibodies
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
ES2729603T3
(es)
|
2012-06-27 |
2019-11-05 |
Merck Sharp & Dohme |
Anticuerpos IL-23 antihumanos cristalinos
|
AU2013285422B2
(en)
|
2012-07-04 |
2017-04-27 |
F. Hoffmann-La Roche Ag |
Covalently linked antigen-antibody conjugates
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
US20140227250A1
(en)
|
2012-08-23 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to tslp
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
EP2919812A4
(en)
*
|
2012-11-19 |
2016-05-18 |
Merck Sharp & Dohme |
Liquid formulations for TNFR: FC fusion proteins
|
EP2931311A4
(en)
|
2012-12-13 |
2016-08-17 |
Merck Sharp & Dohme |
LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
|
US9700633B2
(en)
|
2013-01-28 |
2017-07-11 |
Jenkem Technology Co., Ltd., Tianjin Branch |
Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
|
KR102401525B1
(ko)
|
2013-03-13 |
2022-05-24 |
씨젠 인크. |
사이클로덱스트린 및 항체-약물 포합체 제형
|
AU2014295052B2
(en)
|
2013-07-23 |
2018-08-30 |
Novaliq Gmbh |
Stabilized antibody compositions
|
TWI649308B
(zh)
|
2013-07-24 |
2019-02-01 |
小野藥品工業股份有限公司 |
喹啉衍生物
|
KR102651018B1
(ko)
|
2013-09-11 |
2024-03-27 |
이글 바이오로직스 인코퍼레이티드 |
점도저하제를 함유하는 액체 단백질 제형
|
ES2728578T3
(es)
|
2013-09-20 |
2019-10-25 |
Bristol Myers Squibb Co |
Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores
|
WO2015057541A1
(en)
|
2013-10-16 |
2015-04-23 |
Merck Sharp & Dohme Corp. |
Method of obtaining thermostable dried vaccine formulations
|
RU2589691C2
(ru)
|
2014-06-16 |
2016-07-10 |
Общество с ограниченной ответственностью "Промоген-МАТ" |
Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения
|
WO2015196091A1
(en)
|
2014-06-20 |
2015-12-23 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
CN114984228A
(zh)
|
2014-07-18 |
2022-09-02 |
阿德瓦希斯股份有限公司 |
用于治疗前列腺癌的pd-1拮抗剂和基于李斯特菌的疫苗的组合
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
LT3179992T
(lt)
|
2014-08-11 |
2022-06-27 |
Acerta Pharma B.V. |
Btk inhibitoriaus, pd-1 inhibitoriaus ir (arba) pd-l1 inhibitoriaus terapiniai deriniai
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
MY184288A
(en)
|
2014-08-19 |
2021-03-30 |
Merck Sharp & Dohme Llc |
Anti-tigit antibodies
|
JP2017526700A
(ja)
*
|
2014-09-08 |
2017-09-14 |
セルジーン コーポレイション |
抗pd1若しくは抗pdl1モノクローナル抗体と組み合わせてシチジン類似体の経口製剤を使用する疾患または障害の治療方法
|
WO2016081384A1
(en)
|
2014-11-17 |
2016-05-26 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
BR112017013385A2
(pt)
|
2014-12-23 |
2018-02-06 |
Bristol-Myers Squibb Company |
anticorpos para tigit
|
EP3237000A1
(en)
|
2014-12-23 |
2017-11-01 |
Pfizer Inc |
Stable aqueous antibody formulation for anti tnf alpha antibodies
|
JP2018502123A
(ja)
|
2015-01-20 |
2018-01-25 |
イミューンエクサイト, インコーポレイテッド |
癌免疫療法のための組成物及び方法
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
KR20170122809A
(ko)
|
2015-03-04 |
2017-11-06 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
CN108136001B
(zh)
|
2015-04-03 |
2022-07-29 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
MY188749A
(en)
|
2015-04-17 |
2021-12-28 |
Bristol Myers Squibb Co |
Compositions comprising a combination of nivolumab and ipilimumab
|
EP3839510A3
(en)
*
|
2015-04-17 |
2021-08-25 |
Merck Sharp & Dohme Corp. |
Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
|
ES2861352T3
(es)
|
2015-04-28 |
2021-10-06 |
Bristol Myers Squibb Co |
Tratamiento del melanoma positivo para PD-L1 utilizando un anticuerpo anti-PD-1
|
AU2016271018A1
(en)
|
2015-05-29 |
2017-11-30 |
Dynavax Technologies Corporation |
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
|
TWI773646B
(zh)
*
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
CN114853891A
(zh)
*
|
2015-07-22 |
2022-08-05 |
索伦托药业有限公司 |
与lag3结合的抗体治疗剂
|
EP3334757A4
(en)
|
2015-08-14 |
2019-04-03 |
Merck Sharp & Dohme Corp. |
ANTI-TIGIT ANTIBODIES
|
EA201890618A1
(ru)
|
2015-09-01 |
2018-10-31 |
Ферст Вэйв Байо, Инк. |
Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
|
AU2016316730B2
(en)
|
2015-09-02 |
2023-05-25 |
Immutep S.A.S. |
Anti-LAG-3 Antibodies
|
AU2016322934A1
(en)
|
2015-09-14 |
2018-04-12 |
Compass Therapeutics Llc |
Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
|
CR20180225A
(es)
|
2015-09-25 |
2018-07-09 |
Genentech Inc |
Anticuerpo anti-tigit y métodos de uso
|
CN106999591B
(zh)
|
2015-09-28 |
2021-02-23 |
苏州盛迪亚生物医药有限公司 |
一种抗pd-1抗体制剂及其在医药上的应用
|
US20170097333A1
(en)
*
|
2015-09-28 |
2017-04-06 |
Merck Sharp & Dohme Corp. |
Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
|
EP3356413B1
(en)
|
2015-10-01 |
2022-01-05 |
Potenza Therapeutics, Inc. |
Anti-tigit antigen-binding proteins and methods of use thereof
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
KR20180078329A
(ko)
|
2015-11-25 |
2018-07-09 |
주식회사 레고켐 바이오사이언스 |
분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
|
US20190010224A1
(en)
|
2015-12-22 |
2019-01-10 |
Merck Sharp & Dohme Corp. |
Formulations of engineered anti-il-10 antibodies
|
DK3405490T3
(da)
|
2016-01-21 |
2022-01-10 |
Pfizer |
Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf
|
BR112018072986A2
(pt)
|
2016-05-18 |
2019-03-06 |
Boehringer Ingelheim International Gmbh |
anticorpos anti-pd-1 e anti-lag3 para tratamento de câncer
|
AU2017285218A1
(en)
|
2016-06-14 |
2018-12-06 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
US20190374639A1
(en)
|
2016-11-21 |
2019-12-12 |
Polpharma Biologics S.A. |
Aqueous pharmaceutical formulations
|
TWI761453B
(zh)
|
2017-03-01 |
2022-04-21 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
EP3797792A1
(en)
|
2017-03-01 |
2021-03-31 |
MedImmune Limited |
Formulations of anti-gm-csfralpha monoclonal antibody
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
EP3618871A4
(en)
|
2017-05-02 |
2021-01-06 |
Merck Sharp & Dohme Corp. |
ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
AU2018261080A1
(en)
|
2017-05-02 |
2019-11-07 |
Merck Sharp & Dohme Llc |
Stable formulations of anti-TIGIT antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof
|
CA3060695A1
(en)
|
2017-05-02 |
2018-11-08 |
Merck Sharp & Dohme Corp. |
Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
|
CN111107873A
(zh)
|
2017-09-05 |
2020-05-05 |
默沙东公司 |
用于降低生物制剂粘度的化合物
|
US20220002410A1
(en)
|
2018-11-07 |
2022-01-06 |
Merck Sharp & Dohme Corp. |
Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
BR112023005377A2
(pt)
|
2020-09-24 |
2023-04-25 |
Merck Sharp & Dohme Llc |
Formulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e variantes de hialuronidase e fragmentos das mesmas e métodos de uso das mesmas
|